139 related articles for article (PubMed ID: 29460668)
1. Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision.
Chen DT; Ko TM; Allen AA; Bonnie RJ; Suratt CE; Appelbaum PS; Nunes EV; Friedmann PD; Lee JD; Gordon MS; McDonald R; Wilson D; Boney TY; Murphy SM; O'Brien CP
J Empir Res Hum Res Ethics; 2018 Apr; 13(2):160-172. PubMed ID: 29460668
[TBL] [Abstract][Full Text] [Related]
2. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
Springer SA; Brown SE; Di Paola A; Altice FL
Drug Alcohol Depend; 2015 Dec; 157():158-65. PubMed ID: 26560326
[TBL] [Abstract][Full Text] [Related]
3. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision.
Allen AA; Chen DT; Bonnie RJ; Ko TM; Suratt CE; Lee JD; Friedmann PD; Gordon M; McDonald R; Murphy SM; Boney TY; Nunes EV; O'Brien CP
J Subst Abuse Treat; 2017 Oct; 81():66-72. PubMed ID: 28847457
[TBL] [Abstract][Full Text] [Related]
4. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
5. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
Bahji A; Carlone D; Altomare J
Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
7. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of oral naltrexone for treating opioid-dependent offenders.
Coviello DM; Cornish JW; Lynch KG; Alterman AI; O'Brien CP
Am J Addict; 2010; 19(5):422-32. PubMed ID: 20716305
[TBL] [Abstract][Full Text] [Related]
9. Methadone maintenance treatment may improve completion rates and delay opioid relapse for opioid dependent individuals under community corrections supervision.
Clark CB; Hendricks PS; Lane PS; Trent L; Cropsey KL
Addict Behav; 2014 Dec; 39(12):1736-40. PubMed ID: 25117851
[TBL] [Abstract][Full Text] [Related]
10. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
11. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
12. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
13. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Nayak SM; Huhn AS; Bergeria CL; Strain EC; Dunn KE
Drug Alcohol Depend; 2021 Apr; 221():108649. PubMed ID: 33640679
[TBL] [Abstract][Full Text] [Related]
14. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
[TBL] [Abstract][Full Text] [Related]
15. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
[TBL] [Abstract][Full Text] [Related]
16. Criminal justice continuum for opioid users at risk of overdose.
Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
[TBL] [Abstract][Full Text] [Related]
17. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.
Biondi BE; Frank CA; Forray A; Springer SA
Subst Abus; 2021; 42(4):905-911. PubMed ID: 33750285
[No Abstract] [Full Text] [Related]
18. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
[TBL] [Abstract][Full Text] [Related]
19. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
20. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
